Bangladesh to get 40 lakh doses of Russian vaccine by May: DGDA
Bangladesh approved Sputnik V Covid -19 vaccine for emergency use
Bangladesh will get 40 lakh doses of Russian Sputnik V Covid-19 vaccine by May, said Major General Mahbubur Rahman, director general of of the Directorate General of Drug Administration (DGDA).
"Russian vaccine was approved today. In future we will approve Chinese Sinopharm Covid-19 vaccine," he said in a briefing after a meeting on Tuesday.
"There is no doubt about our capability to produce vaccines," DG said.
Keep updated, follow The Business Standard's Google news channel
Incepta Pharmaceuticals produces 14 vaccines which are exported abroad. They can produce vaccines in any format, he said adding that "Our capability is much higher."
Vaccines could be produced in the country through technology sharing or will be brought in bulk and final finishing will be made here.
The country needs vaccine. Government is trying to get a vaccine from an alternative source for the country, said Mahbubur Rahman.
The Sputnik vaccine can be kept at a temperature of 2-8 degrees.The vaccine will be brought officially and vaccination activities will continue officially, added the DG.
Bangladesh approved Russian Sputnik V Covid -19 vaccine for emergency use in the country.
The decision was disclosed at a meeting of the Directorate General of Drug Administration (DGDA) today.
The approval was given by the Committee on Emergency Public Health Medicines, Experimental Medicines, Vaccines and Medical Equipment formed by the Ministry of Health.
Now there are no legal restrictions on the import and use of this Russian vaccine, according to DGDA.
Earlier, Russia proposed to manufacture its 'Sputnik' Covid-19 vaccine in Bangladesh in collaboration with the local pharmaceuticals under a co-production arrangement while Bangladesh is searching other sources apart from India to get the much demanded inoculation.
In the wake of an uncertainty over the supply of vaccines from Indian Serum Institute, the government on 20 April formed a committee to send recommendations to the Prime Minister's Office by Monday on using alternatives to the Oxford-AstraZeneca vaccine for continuing the mass Covid vaccination programme.
The committee recommended that vaccines from Chinese company Sinopharm and Sputnik V of Russia be used as alternatives to the Oxford-AstraZeneca Covid-19 vaccine manufactured by Serum Institute of India.
